The market for hip and knee implants is stable but mired in a low-growth stage, according to analysts who attended the American Academy of Orthopedic Surgeons conference in San Francisco last week.
Although the abrupt departure of Stryker CEO Steve MacMillan drew the lion’s share of attention at the AAOS event, analysts from Barclays Capital and Leerink Swann agreed that the sector’s outlook calls for low-single-digit growth.
Cordis Corp., the stent-making division of Johnson & Johnson (NYSE:JNJ) inked a worldwide distribution deal with Ostial Solutions for a stent-positioning system designed to treat aorto-ostial blockages.
Kalamazoo, Mich.-based Ostial makes the Ostial Pro stent positioning system, which it sells in the U.S. Under the terms of the deal with Bridgewater, N.J.-based Cordis, the J&J subsidiary plans to roll the system out worldwide during the first half of 2011.
MassDevice Network
@MassDevice
LinkedIn
YouTube